# Effectiveness and Safety of MMSCs for Enhancing Hematopoietic Recovery and Prophylaxis of Neutropenic Enterocolitis

> **NCT02145923** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Burnasyan Federal Medical Biophysical Center** · enrollment: 16 (estimated)

## Conditions studied

- Neutropenic Enterocolitis
- Myeloablative Chemotherapy Induced Bone Marrow Aplasia

## Interventions

- **PROCEDURE:** Peripheral blood stem cell mobilisation and collection
- **DRUG:** High-dose chemotherapy
- **DRUG:** Bone marrow derived allogeneic MMSCs infusion
- **PROCEDURE:** Autologous peripheral blood stem cells infusion

## Key facts

- **NCT ID:** NCT02145923
- **Lead sponsor:** Burnasyan Federal Medical Biophysical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-05
- **Primary completion:** 2016-06
- **Final completion:** 2016-12
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2015-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02145923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02145923, "Effectiveness and Safety of MMSCs for Enhancing Hematopoietic Recovery and Prophylaxis of Neutropenic Enterocolitis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02145923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*